Literature DB >> 29403601

Author's Reply.

Georgios D Panos1, Zisis Gatzioufas2.   

Abstract

Entities:  

Year:  2018        PMID: 29403601      PMCID: PMC5782468          DOI: 10.4103/jovr.jovr_232_17

Source DB:  PubMed          Journal:  J Ophthalmic Vis Res        ISSN: 2008-322X


× No keyword cloud information.
Dear Editor, We would like to thank Dr. Mohan for his comments and for sharing his interesting case with us. We fully agree that extended retinal nerve myelination combined with high myopia is associated with treatment refractory amblyopia. However, the literature reports positive treatment outcomes in a number of cases of myopia and amblyopia related to unilateral myelinated nerve fibers.[12] According to Hittner and Antoszyk, the status of the macula is the main prognostic factor for final visual outcomes in these cases.[1] This observation is also supported by Kodama et al.[3] In our case, funduscopy did not reveal any obvious macular or optic nerve pathology. Moreover, the baseline best corrected visual acuity was 20/60, which is significantly higher than in the case reported by Dr. Mohan with the patient only being able to count fingers close to face. We believe that the absence of obvious macular and optic disc anomalies is the reason that our patient recovered partially after treatment with glasses and patching of the fellow eye.

Financial Support and Sponsorship

Nil.

Conflicts of Interest

There are no conflicts of interest.
  3 in total

1.  Myelinated retinal nerve fibers: prevalence, location and effect on visual acuity.

Authors:  T Kodama; S Hayasaka; T Setogawa
Journal:  Ophthalmologica       Date:  1990       Impact factor: 3.250

2.  Unilateral peripapillary myelinated nerve fibers with myopia and/or amblyopia.

Authors:  H M Hittner; J H Antoszyk
Journal:  Arch Ophthalmol       Date:  1987-07

3.  Unexpected good results after therapy for anisometropic amblyopia associated with unilateral peripapillary myelinated nerve fibers.

Authors:  C G Summers; L Romig; J D Lavoie
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1991 May-Jun       Impact factor: 1.402

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.